This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders USA
New Data, Case Studies & Partners
September 4th-5th, 2024San Diego Convention Center, USA

David Slack
CEO at Impilo Therapeutics
Chair

Profile

David Slack is an industry veteran with over 30 years’ experience in public and private biotech as well as large pharmaceutical companies. He has been responsible for numerous company financings, strategic alliances, mergers and acquisitions, and other partnerships. He joined the Board of Impilo predecessor company, Cend Therapeutics, in October 2019 and was appointed President and CEO in June 2020. David oversaw the merger of Cend with Caladrius Biosciences to form Lisata Therapeutics in 2022 and served as President and Director of Lisata. He then co-founded Impilo Therapeutics to enable to nucleic acid-based medicine to effectively treat solid tumor cancers Previously, David served as co-founding Chief Business Officer at Viracta Therapeutics. David served as Vice President for Business Development at Ionis Pharmaceuticals and in senior management positions as Rhône-Poulenc Rorer, RPR Gencell and Aventis Pharmaceuticals.

Agenda Sessions

  • Chair:

    3:50pm